(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(43) International publication date
29 April 2004 (29.04.2004)

PCT

(10) International publication number

WO 2004/035561 A1

(51) International patent classification⁷:
C07D 307/86, 307/94, 405/12, 213/48, C07C

C07D 307/86, 307/94, 405/12, 213/48, C07C 47/548, 47/55, A61K 31/343, A61P 25/18

(21) International application number:

PCT/FR2003/003053

(22) International filing date:

16 October 2003 (16.10.2003)

(25) Language of filing:

French

(26) Language of publication:

French

(30) Data relating to the priority:

02/12,854

16 October 2002 (16.10.2002)

FR

(71) Applicant (for all designated States except US): PIERRE FABRE MEDICAMENT [FR/FR]; 45, place Abel-Gance, F-92100 Boulogne-Billancourt (FR).

(72) Inventors; and

(75) Inventors/Applicants (US only): VACHER, Bernard [FR/FR]; 5, rue des Cigales, F-81100 Castres (FR). CUISIAT, Stéphane [FR/FR]; 13, rue du Pasteur Henri Bosc, Votissement les Carlines, F-81100 Castres (FR) (KOEK, Wouter [NL/US];

228 Fleetwood Drive, San Antonio, TX 78232 (US). COLPAERT, Francis [BE/FR]; Domaine de Mirabel, F-81700 Puylaurens (FR).

- (74) Representatives: MARTIN, Jean-Jacques, etc.; Cabinet Regimbeau, 20, rue de Chazelles, F-75847 Paris Cedex 17 (FR).
- (81) Designated states (national): AU, BR, CA, CN, JP, MX, US, ZA.
- (84) Designated states (regional): European Patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

Declaration under Rule 4.17:

Of inventorship (Rule 4.17(iv)) for the following designation US.

Published:

- With International Search Report.

[continued on next page]

As printed

(54) Title: 3-(CYCLOPENTEN-1-YL)-BENZYL- OR 3-(CYCLOPENTEN-1-YL)-HETEROARYLMETHYL-AMINE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING SCHIZOPHRENIA

(54) Titre : DERIVES DE 3-(CYCLOPENTEN-1-YL)-BENZYL- OU 3-(CYCLOPENTEN-1-YL)-HETEROARYLME-THYL-AMINES ET LEUR UTILISATION A TITRE DE MEDICAMENTS POUR LE TRAITEMENT DE LA SCHIZOPHRENIE

(57) Abstract: The invention concerns compounds of general formula (I), wherein: (a) represents a single bond or a double bond; W represents a CH, CH₂, CHCH₃, CCH₃, C(CH₃)₂ group, a C(CH₂)₂ group (i.e., a carbon atom bearing two methylene groups bound together to form a spiro-cyclopropane unit) or a C(CH₂)₃ group (i.e., a carbon atom bearing two methylene groups bound together to form a spiro-cyclobutane unit) provided that when (a) is a double bond

then W exclusively represents a CH or CCH₃ group and when (a) is a single bond, then W exclusively represents a CH₂, CHCH₃, $C(CH_3)_2$, $C(CH_2)_2$ or $C(CH_2)_3$ group; X is a carbon atom bearing a hydrogen atom (CH) or a nitrogen atom; Y is a carbon atom bearing a hydrogen atom or a fluorine atom, their additive salts and optionally the hydrates of additive salts with pharmaceutically acceptable mineral acids or organic acids as well as their tautomeric forms, pure entantiomers and enantiomer mixtures whether racemic or not.

(57) Abrégé: L'invention concerne des composés de formule générale (1) dans laquelle: (a) représente une liaison simple ou une liaison double; W représente un groupe CH, CH₂, CHCH₃, CCH₃, C(CH₃)₂, un groupe C(CH₂)₂ (i.e., un atome de carbone portant deux groupes méthylènes liés entre eux de manière à former un motif spiro-cyclopropane) ou C(CH₂)₃ (i.e., un atome de carbone portant deux groupes méthylènes liés à un autre groupe méthylène de manière à former un motif spiro-cyclobutane) avec la réserve, toutefois, que lorsque (a) est une liaison double alors W représente exclusivement un groupe CH ou CCH₃ et que, lorsque (a) est une liaison simple, alors W représente exclusivement un groupe CH₂, C(CH₃)₂, C(CH₂)₃ ou C(CH₂)₃; X est un atome de carbone portant un atome d'hydrogène (CH) ou un atome d'azote; Y est un atome d'hydrogène ou un atome de fluor; leurs sels d'addition et éventuellement les hydrates des sels d'addition avec les acides minéraux ou les acides organiques pharmaceutiquement acceptables ainsi que leurs formes tautomères, les énantiomères purs et les mélanges d'énantiomères racémique ou non.


4/035561 A1

WO 2004/035561 A1

before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For an explanation of the two-letter codes and the other abbreviations, reference is made to the explanations ("Guidance Notes on Codes and Abbreviations") at the beginning of each regular edition of the PCT Gazette.

INTERNATIONAL SEARCH REPORT



According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

 $\begin{array}{ll} \mbox{Minimum documentation searched (classification system followed by classification symbols)} \\ \mbox{IPC 7} & \mbox{C07D} & \mbox{C07C} & \mbox{A61K} & \mbox{A61P} \end{array}$

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, BEILSTEIN Data

Category *	Citation of document, with indication, where appropriate, of t	the relevant passages	Relevant to claim No.
1	WO 99 58527 A (EGYT GYOGYSZERN GYAR ;IVANICSNE MEGYERI KATALI 18 November 1999 (1999-11-18) claims	1-6	
1	WO 00 58282 A (KOEK WOUTER ;PF (FR); VACHER BERNARD (FR); CUI 5 October 2000 (2000-10-05) cited in the application claims		
1	WO 99 51575 A (AMERICAN HOME I 14 October 1999 (1999-10-14) cited in the application claims	PROD)	1-6
	`		
<u> </u>	her documents are listed in the continuation of box C.	χ Patent family members are liste	ed in annex.
A docume consider earlier of filing of the document of the consideration	alegories of cited documents : ent defining the general state of the art which is not dered to be of particular relevance document but published on or after the international tate ent which may throw doubts on priority claim(s) or	*T* later document published after the in or priority date and not in conflict will cited to understand the principle or invention *X* document of particular relevance; the cannot be considered novel or cannot be considered novel or the cannot be considered novel or cannot b	nternational filing date tith the application but theory underlying the e claimed invention not be considered to document is taken alone
P docume	ategories of cited documents : ent defining the general state of the art which is not dered to be of particular relevance document but published on or after the international date	*T" later document published after the in or priority date and not in conflict will cited to understand the principle or invention "X" document of particular relevance; the cannot be considered novel or cannot be considered novel.	nternational filing date ith the application but theory underlying the e claimed invention not be considered to document is taken alone e claimed invention inventive step when the more other such docu- vious to a person skilled
P Special ca PA docume consider PE earlier of filling of the citation other of the citation	ategories of cited documents: ent defining the general state of the art which is not dered to be of particular relevance document but published on or after the international tate ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another n or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or means ent published prior to the international filing date but	"T" later document published after the in or priority date and not in conflict will cited to understand the principle or invention "X" document of particular relevance; the cannot be considered novel or cannot involve an inventive step when the "Y" document of particular relevance; the cannot be considered to involve an document is combined with one or ments, such combination being obvin the art.	International filing date with the application but theory underlying the elaimed invention to be considered to document is taken alone e claimed invention inventive step when the more other such docurrious to a person skilled ant family
A' docume consider decume which citation of the production of the control of the citation of t	ategories of cited documents: ent defining the general state of the art which is not dered to be of particular relevance document but published on or after the international date ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another n or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or means ent published prior to the international filing date but than the priority date claimed	*T" later document published after the in or priority date and not in conflict will cited to understand the principle or invention *X' document of particular relevance; the cannot be considered novel or cannot involve an inventive step when the "Y' document of particular relevance; the cannot be considered to involve an document is combined with one or ments, such combination being obvin the art. *&' document member of the same pate	International filing date with the application but theory underlying the elaimed invention to be considered to document is taken alone e claimed invention inventive step when the more other such docurrious to a person skilled ant family
P docume which citation of the Date of the	ent defining the general state of the art which is not dered to be of particular relevance document but published on or after the international state ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another nor other special reason (as specified) ent referring to an oral disclosure, use, exhibition or means ent published prior to the international filing date but han the priority date claimed	*T" later document published after the in or priority date and not in conflict will cited to understand the principle or invention *X' document of particular relevance; the cannot be considered novel or canninvolve an inventive step when the *Y' document of particular relevance; the cannot be considered to involve an document is combined with one or ments, such combination being obvin the art. *&' document member of the same pate	International filing date with the application but theory underlying the elaimed invention to be considered to document is taken alone e claimed invention inventive step when the more other such docurrious to a person skilled ant family

INTERNATIONAL SEARCH REPORT

Internation Application No PCT 03/03053

Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	PCT, 03/03053		
ategory °		Relevant to claim No.		
<u>.</u>	CHEMICAL ABSTRACTS, vol. 119, no. 17, 25 October 1993 (1993-10-25) Columbus, Ohio, US; abstract no. 180657, YANUSAGA T. ET AL: "Preparation of (hetero)aryloxyalkylamine derivatives having selective affinity to serotonin (5-HT 1A)receptors" XP002245145	1-6		
	abstract & JP 05 125024 A (YAMANOUCHI PHARMA COLTD) 21 May 1993 (1993-05-21) cited in the application			
	-			

INTERNATIONAL SEARCH REPORT

Į	NIERN	ERNATIONAL SEAR		CH REPORT			
	Inr	on on patent family me			Internation Application No		
					PCT	u3/03053	
Patent document cited in search report		Publication		Patent family		Publication	
		date		member(s)		date	
W0 9958527	Α	18-11-1999	HU	980108	5 A2	28-08-2000	
			HU	9801086	5 A2	28-08-2000	
			ΑU	753706	5 B2	24-10-2002	
		•	ΑU	4052999) A	29-11-1999	
			CA	2332275	5 A1	18-11-1999	
			ΕP	1077973	3 A2	28-02-2001	
			HR	20000750) A1	30-06-2001	
			WO	9958527		18-11-1999	
			JP	2002514643	B T	21-05-2002	
			PL	345309		03-12-2001	
			SK	17212000) A3	10-05-2001	
WO 0058282	Α	05-10-2000	FR	2791676		06-10-2000	
			ΑŢ	227714		15-11-2002	
			ΑÜ	3661400		16-10-2000	
			CA	2366820		05-10-2000	
			DE	60000790		19-12-2002	
	•		DE	60000790		02-10-2003	
			DK	1187824		10-03-2003	
			EP	1187824		20-03-2002	
			ES	2186639		16-05-2003	
			WO	0058282		05-10-2000	
			PT	1187824		31-03-2003	
			US	6417222	B1	09-07-2002	
WO 9951575	Α	14-10-1999	AU	3386199	Α	25-10-1999	
			CA	2327359		14-10-1999	
			CN	1304403		18-07-2001	
			EP	1070050		24-01-2001	
			JP	2002510675		09-04-2002	
			WO	9951575		14-10-1999	
 JP 05125024	Α	21-05-1993	NONE				
	П	£1-00-1333	NONE				